Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS), has been published in the peer reviewed journal, Annals of Clinical and Translational Neurology.
The paper, authored by coordinating investigator, Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, is entitled, "Safety and efficacy of vidofludimus calcium, a selective dihydroorotate dehydrogenase inhibitor, in relapsing-remitting multiple sclerosis (EMPhASIS): a double-blind, randomized, placebo-controlled phase 2 trial." It can be accessed through the following link: https://onlinelibrary.wiley.com/doi/10.1002/acn3.51574.
Vidofludimus calcium is a novel and second generation selective dihydroorotate dehydrogenase (DHODH) inhibitor without off-target effects on kinases seen with drugs of the same class, which may lead to a better safety and tolerability profile. The inhibition of DHODH has been shown to suppress magnetic resonance imaging (MRI) brain lesions and disease activity in multiple sclerosis. The paper assessed the safety and activity on MRI-based endpoints as well as clinical and biomarker assessments of vidofludimus calcium in patients with RRMS.
https://finance.yahoo.com/news/immunic-announces-publication-data-phase-103000738.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.